Welcome to our dedicated page for Beyond Air news (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air stock.
Beyond Air, Inc. develops and commercializes nitric oxide-based medical device and biopharmaceutical programs. Its recurring news centers on LungFit PH, a tankless inhaled nitric oxide system that uses Plasma Pulse Technology to generate nitric oxide from room air, and on commercial access through hospital purchasing channels.
Company updates also cover nitric oxide programs for respiratory indications, including severe lung infections, and Beyond Cancer's ultra-high concentration nitric oxide, or UNO, platform for investigational solid-tumor immunotherapy. Additional recurring themes include clinical data presentations, scientific publications, intellectual property, leadership changes, investor conferences, and governance matters.
Beyond Air, Inc. (NASDAQ: XAIR) reported positive interim results from its ongoing pilot study using 150 ppm nitric oxide (NO) via LungFit® PRO for treating acute viral pneumonia, including COVID-19. The study showed that NO treatment was well-tolerated, with no treatment-related adverse events identified. In addition, data from three bronchiolitis pilot trials indicated a favorable safety profile and consistent efficacy. The firm is preparing for a pivotal study based on these encouraging signals supporting further development of LungFit® PRO in hospitalized patients with viral pneumonia.
Peter Senior Appointed Director of Business Development at Beyond Air
Beyond Air, Inc. (NASDAQ: XAIR) has announced the appointment of Peter Senior as Director of Business Development. Senior, with 26 years of experience at Linde plc, brings extensive knowledge in the global gas business, particularly in nitric oxide. His leadership is expected to enhance the development of the LungFit® product line, which focuses on treating respiratory conditions and solid tumors. The company aims to secure international partnerships to further advance its innovative therapeutic technologies.
Beyond Air, Inc. (NASDAQ: XAIR) has announced that CEO Steve Lisi will participate in two virtual investor conferences in May 2021. The first event is the 7th Annual Truist Securities 2021 Life Sciences Summit on May 4-5, where Lisi will engage in a fireside chat on May 4 at 11:20 AM ET. The second event is the Oppenheimer MedTech Summit on May 26, where he will be available for virtual 1-on-1 meetings. Beyond Air specializes in developing inhaled nitric oxide for respiratory conditions and is advancing its LungFit® system for treating serious lung infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced its participation in the American Thoracic Society International Conference 2021, presenting two abstracts on inhaled nitric oxide. The first abstract evaluates the efficacy and safety of inhaled nitric oxide for treating acute bronchiolitis, while the second focuses on its potential in treating COVID-19 and other viral pneumonias in adults. The conference is scheduled virtually from May 14-19, 2021. Beyond Air is advancing its innovative LungFit® system, designed for delivering nitric oxide for various pulmonary conditions.
Beyond Air, Inc. (NASDAQ: XAIR) has announced that CEO Steve Lisi will participate in two virtual investor conferences in March 2021. The conferences are the 33rd Annual Roth Conference, scheduled from March 15-17, and the Oppenheimer 31st Annual Healthcare Conference on March 16-18, with Lisi presenting on March 16 at 9:20 AM ET. Beyond Air focuses on developing inhaled nitric oxide treatments for serious lung infections and pulmonary hypertension, utilizing their innovative LungFit™ system.
Beyond Air, Inc. (NASDAQ: XAIR) has secured up to $2.17 million from the Cystic Fibrosis Foundation to advance its LungFit™ GO pilot study targeting Nontuberculous Mycobacteria (NTM) pulmonary disease. This 12-week trial in Australia aims to enroll around 20 patients suffering from refractory mycobacterial lung infections. Interim data is expected mid-2021, with topline results anticipated six months later. The funding will support the self-administration of high concentration nitric oxide (NO) for improved treatment outcomes, particularly for cystic fibrosis patients.
Beyond Air (NASDAQ: XAIR) announced its FDA is reviewing the premarket approval (PMA) for LungFitTM PH to treat persistent pulmonary hypertension of the newborn (PPHN), potentially launching this summer. The company reported a revenue of $149,000 for Q3 2020, down from $314,000 in Q3 2019, with a net loss of $5.8 million, or ($0.33) per share. Their ongoing studies include acute viral pneumonia and Nontuberculous Mycobacteria treatments. Cash reserves stand at $22.7 million as of December 31, 2020. A conference call is scheduled for February 9th at 4:30 PM ET.
Beyond Air, Inc. (NASDAQ: XAIR) announces its financial results for the third fiscal quarter ending December 31, 2020. The report is scheduled for February 9, 2021, with a dedicated conference call at 4:30 PM ET. The company focuses on developing inhaled nitric oxide for various respiratory conditions and solid tumors, aiming to improve treatment options for severe lung infections like SARS-CoV-2. Beyond Air's innovative LungFit™ system delivers precise amounts of nitric oxide, targeting pulmonary diseases and advancing in clinical trials.
Beyond Air (NASDAQ: XAIR) has initiated a pilot clinical trial for its LungFit™ GO device targeting nontuberculous mycobacteria (NTM) lung disease, expected to enroll 20 adult patients in Australia. The 12-week, open-label study will first dose patients in January 2021 and report interim findings mid-2021. LungFit™ GO aims to provide at-home treatment options for patients with chronic respiratory conditions, potentially improving quality of life and outcomes for those with severe lung infections.
Beyond Air, Inc. (NASDAQ: XAIR) announced that Steve Lisi, its CEO, will participate in the 32nd Annual Piper Sandler Healthcare Conference virtually from December 1-3, 2020. The company will provide a pre-recorded investor presentation and engage in virtual one-on-one meetings.
Beyond Air is focused on developing inhaled nitric oxide (NO) therapies for respiratory conditions, including severe infections and pulmonary hypertension. Its LungFit™ device generates NO from ambient air, potentially treating various pulmonary diseases.